[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thoracic-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thoracic-cancers":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":4,"leadSponsor":47,"locationsCount":50},"100075905","evaluation-of-cell-changes-in-blood-and-tissue-in-cancers-of-the-lung-esophagus-and-lung-lining-100075905",false,"NCT00242723","Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining","Prospective Evaluation of Genetic and Epigenetic Alterations in Patients With Thoracic Malignancies","* INCLUSION CRITERIA:\n\nIndividuals with potentially malignant or suspicious lesions, or with biopsy proven lung cancers or esophageal cancers, malignant pleural mesotheliomas, mediastinal or chest wall neoplasms, thymoma\u002Fthymic carcinomas, or thoracic metastases from cancers of non-thoracic origin.\n\nIndividuals must have an ECOG performance score of 0-2.\n\nParticipants must:\n\n-Have physical examination parameters within acceptable limits by standard of practice guidelines prior to clinically indicated surgical procedure (e.g., biopsy or surgery),\n\nand\n\n-Be aware of the nature of his\u002Fher illness,\n\nand\n\n-Must be willing to undergo clinically indicated standard intervention that may include endoscopic biopsies of tumor and adjacent normal tissues (i.e., other tissue necessary to obtain negative margins per standard of care surgical processes) as a part of their standard of care treatment plan.\n\nParticipants must agree to provide blood and urine samples to support ongoing laboratory research endeavors pertaining to the epigenetics of thoracic malignancies.\n\nIndividuals must be 2 years of age or older. Note: Individuals \\>= 2 and \\\u003C 18 years of age may only participate in research sample collection if the tissue acquisition is performed during a clinically indicated surgical procedure (e.g., biopsy or surgery), and the biospecimen sampling (e.g., blood, urine, \\[clinically indicated\\] resected tumor tissue) does not add risk to the clinically indicated procedures.\n\nAbility of participant, their parents\u002Fguardians or legally authorized representative (LAR) to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nNone.","ALL","2 Years","120 Years",{"count":20,"type":21},1559,"ESTIMATED","OBSERVATIONAL","Background:\n\n* Chromatin is is the structural building block of a chromosome. It is found inside the nucleus of the cell and consists of a complex of DNA and protein.\n* Cancers of the lung, pleura (lung lining) and esophagus show profound changes in chromatin structure that may affect the course of disease in participants.\n* A better understanding of these diseases and the genetic changes associated with them may be helpful in developing new treatments for them.\n\nObjectives:\n\n* To medically evaluate individuals with potential (medically suspicious) or proven cancer of the lung, esophagus, pleura, mediastinum or chest wall, or cancers of other origin that have invaded the lung, and then, to determine eligibility for NCI investigational treatment studies for participants \\>18 years of age (adult participants only).\n* To use clinically obtained biopsies (small pieces of tissue) of tumor and adjacent normal tissue from clinically indicated procedures (standard of care biopsy or surgery), as well as blood and urine samples, from participants with cancer of the lung, esophagus, pleura, mediastinum or chest wall, or cancers of other origin that have invaded the lung, for research into immune and cellular changes of these cancers. Study research includes genetic testing and the growth of laboratory cell lines from participant samples, to examine how genes change drug metabolism.\n* To permit long-term follow-up of participants with cancer of the lung, esophagus, pleura, mediastinum or chest wall, or cancers of other origin that have invaded the lung, for natural history research on genetics and if the gene expression coincides with clinical response to patient anti-cancer therapies (treatment received at NCI or from participant's own physicians).\n\nEligibility:\n\n* Individuals 2 years of age and older with potential (medically suspicious) or proven cancer of the lung, esophagus, pleura, mediastinum or chest wall, or cancers of other origin that have invaded the lung. Note: Individuals \\>= 2 years of age and under 18 years of age may only participate in research sample collection if the tissue acquisition is performed during a clinically indicated surgical procedure, and the sampling of tissue, blood or urine does NOT add risk to the clinically indicated procedures.\n* Participants must have physical examination parameters within acceptable limits by standard of practice guidelines prior to clinically indicated surgical procedure (standard of care biopsy or surgery).\n\nDesign:\n\n* All participants will undergo standard tests to evaluate the stage of their disease, and then, eligibility determination for NCI investigational treatment studies will be made for participants \\>18 years of age (adult participants only).\n\n  * Participants \\>18 years of age (adult participants only) who are determined to be eligible for a treatment study at NCI are offered participation in that study. No investigational treatment is administered on this protocol.\n  * Participants \\>= 2 years of age (all participants) may receive standard of care treatment at NCI or with their own physician if it is determined that standard of care surgery, radiation, or chemotherapy is more clinically appropriate for that participant's disease status.\n  * Participants who receive standard of care biopsy or surgery (clinically indicated standard staging, surgical intervention, and follow up care) at the NIH Clinical Center are expected to return for a clinical examination visit post-procedure (for instance, 4 weeks after discharge from surgery). After recovery, participants will return to the NIH Clinical Center for study follow-up visits at intervals based on their clinical status (such as every 3 to 36 months) until the end of study participation.\n* Blood and urine samples are collected from all participants for study research at baseline and study visits until the end of study participation. If participants have additional clinically indicated biopsies or surgeries, resected tissue may be collected for study research (as logistically appropriate).\n* It is expected that up to 1,559 participants will be enrolled and followed long-term on this study.",[25,26,27,28,29,30],"Thoracic Cancers","Malignant Pleural Mesotheliomas NOS","Lung Cancer NOS","Esophageal Cancers NOS","Cancers of Non Thoracic Origin With Metastases to the Lungs or Pleura","Thoracic Malignancies",[32,33,34,35,36,37,38,39],"Biopsy","Staging Studies","Screening","potentially malignant or suspicious lesions","Cancer Primary Evaluation","Lung Cancer","Esophageal Cancer","Malignant Pleural Mesothelioma","RECRUITING","2026-08-15",{"date":43,"type":44},"2026-08-18","ACTUAL",{"date":46,"type":44},"2005-11-09",{"name":48,"class":49},"National Cancer Institute (NCI)","NIH",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100568438","feasibility-study-of-cbct-for-igrt-in-cancer-patients-100568438","NCT06681233","Feasibility Study of CBCT for IGRT in Cancer Patients","A Feasibility Study of a Novel Cone-Beam CT Approach for Image Guided Radiotherapy in Cancer Patients","Inclusion Criteria:\n\n1. Patient age ≥ 18\n2. Patient is receiving radiation therapy for head and neck, thorax, liver, breast, genitourinary, or gastrointestinal malignancies\n3. A CBCT acquisition for localization is standard of care for the radiation therapy treatment plan being delivered\n\nExclusion Criteria:\n\n1. Patient has ECOG Performance Status ≥3.\n2. Patient is wheelchair bound.\n3. Patient has a life expectancy \\\u003C3 months.\n4. Patient is unwilling or unable to provide informed consent to participate in the study.\n5. Patient is pregnant or has plans for pregnancy during the period of treatment.\n6. Patient is part of a vulnerable population (per ISO 14155:2020, \"individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response\"). This includes prisoners.","18 Years",{"count":60,"type":21},50,"INTERVENTIONAL",[63],"NA","Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy but CBCT images have poor contrast and are susceptible to imaging artefacts that limit their usability for other tasks in the radiation therapy workflow.\n\nVarian Medical Systems, the sponsor of this study, has developed new CBCT imaging technology called HyperSight that so far has demonstrated increased image quality compared with conventional CBCT images. This new HyperSight CBCT imager has previously been built into Varian Halcyon and Ethos treatment machines, where the imager is enclosed in a ring that rotates around the patient. Now, HyperSight has been built into a Varian treatment machine, called TrueBeam, where the imager is mounted on a C-shaped arm that rotates around you to acquire an image.\n\nThis study is being done to evaluate the image quality of HyperSight CBCT compared to conventional CBCT images, and to determine whether HyperSight CBCT can improve the process of delivering radiation treatments.\n\nThe goal of this study is to collect images from this new HyperSight-TrueBeam CBCT imager from a variety of patients and locations in the body. The images will be analyzed to determine whether their quality is high enough to use for tasks other than positioning patients for treatment. For example, the study will determine whether the HyperSight images could be used to calculate a radiation plan.",[66,67,25,68,69,70],"Head and Neck Cancers","Breast Cancer","Liver Cancer","Genito Urinary Cancer","Gastrointestinal Cancers","2026-03-12",{"date":73,"type":44},"2026-03-13",{"date":75,"type":44},"2025-02-19",{"date":77,"type":21},"2026-09",{"name":79,"class":80},"Varian, a Siemens Healthineers Company","INDUSTRY",4]